MS ECHO: Switching Disease Modifying...
Transcript of MS ECHO: Switching Disease Modifying...
![Page 1: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/1.jpg)
MS ECHO: Switching Disease Modifying
Therapies
Gloria von Geldern, MD Assistant Professor Neurology
![Page 2: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/2.jpg)
Conflicts of Interest
Dr. von Geldern has no conflicts of interest to disclose
![Page 3: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/3.jpg)
Objectives
• When to consider switching disease modifying therapies (DMTs)
• Review risks and benefits of switching DMTs
![Page 4: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/4.jpg)
• 49 year old man
• Diagnosed with MS after left-sided numbness and right leg
weakness with typical lesions on MRI brain and C spine
• No other medical problems
• On Copaxone for 7 months: relapse with left leg weakness
• On Rebif for 1.5 years: 4 new lesions MRI brain, no enhancement
• On Tysabri for 4 years: No relapses, MRI stable
• Now: JCV antibody positive
Case
![Page 5: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/5.jpg)
What are reasons to switch DMTs?
• Inadequate adherence to the treatment regimen • Intolerable side effects or laboratory abnormalities • Sub-optimal treatment response
![Page 6: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/6.jpg)
What are reasons to switch DMTs?
• Inadequate adherence to the treatment regimen • Intolerable side effects or laboratory abnormalities • Sub-optimal treatment response
![Page 7: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/7.jpg)
2648 patients on interferons or Copaxone 25% non-compliant (50.2% forgot, 32% injection site reaction)
Devonshire et al. 2010
Predictors of Adherence
![Page 8: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/8.jpg)
2446 patients, at least 12 months - 59.6% adherent • Less likely to have MS-related hospitalization (OR 0.63, 95% CI 0.47–0.83) • Less MS relapses (OR 0.71, 95% CI 0.59–0.85 • Lower medical costs ($3380 vs. $4348, p=0.003)
Tan et al. 2010
Adherence is Associated with Lower Medical Cost
![Page 9: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/9.jpg)
What are reasons to switch DMTs?
• Inadequate adherence to the treatment regimen • Intolerable side effects or laboratory abnormalities • Sub-optimal treatment response
![Page 10: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/10.jpg)
Coyle, 2013
![Page 11: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/11.jpg)
What are reasons to switch DMTs?
• Inadequate adherence to the treatment regimen • Intolerable side effects or laboratory abnormalities • Sub-optimal treatment response
![Page 12: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/12.jpg)
Coyle, 2013
Breakthrough Disease Activity
![Page 13: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/13.jpg)
No evidence of disease activity (NEDA)
- No relapse
- No worsening of disability (EDSS)
- No new, enlarging or enhancing lesion on MRI
In clinical trials less than 50% of patients
have NEDA over 2 years
What is a realistic goal?
![Page 14: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/14.jpg)
Gajofatto et al. 2009
![Page 15: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/15.jpg)
Rio et al. 2012
![Page 16: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/16.jpg)
Kalincik et al. 2015
![Page 17: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/17.jpg)
• Choice of new DMT depends on reason for switch DMT with different mechanism of action • Consider what tests you need before switching • Decide on wash-out period
How to switch DMTs
![Page 18: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/18.jpg)
Washout
• Period between stopping old and starting a new DMT
• Minimize esp if patient has aggressive disease
• Optimal wash-out period depends on
- pharmacodynamics of old and new DMT
- possible laboratory abnormalities
![Page 19: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/19.jpg)
Washout
• Typically no wash-out needed coming off GA or IFNβ
• Tysabri to Gilenya: ideally <2 months
• Tysabri to Copaxone: may need to overlap?
![Page 20: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/20.jpg)
Jokubaitis et al. 2014
![Page 21: MS ECHO: Switching Disease Modifying Therapiesecho.msrrtc.washington.edu/sites/echo/files/files/Session... · 2015-08-07 · • Changing Therapy in Relapsing Multiple Sclerosis:](https://reader035.fdocuments.in/reader035/viewer/2022070805/5f03e1ab7e708231d40b3aa4/html5/thumbnails/21.jpg)
Resources • Consensus on Disease-Modifying Therapies
– Summary version may be useful when discussing treatment options with patients and advocating with insurers for access and coverage.
• Changing Therapy in Relapsing Multiple Sclerosis: Considerations and Recommendations of a Task Force of the National Multiple Sclerosis Society
• MS Navigator (1-800-FIGHT MS), Society Patient Packets